Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.91 USD | -4.52% | -16.20% | -39.71% |
Jun. 04 | Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses | CI |
May. 09 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.71% | 953M | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- PHVS Stock
- News Pharvaris N.V.
- Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating